Objectives The aim was to evaluate plasma and cerebrospinal fluid (CSF) nimodipine
concentrations in patients with aneurysmal subarachnoid hemorrhage and their correlation …

Background The aim of this study was to evaluate serum nimodipine concentrations in
patients with aneurysmal subarachnoid hemorrhage (SAH) after parenteral therapy and a …

Background The incidence of cerebral infarction and poor outcome in patients with
aneurysmal subarachnoid hemorrhage (aSAH) is reduced by oral nimodipine but acute …

Objective The pharmacokinetics of nimodipine following enteral administration in the early
phase after subarachnoid haemorrhage (SAH) has not been described. If a sufficient …

Object The calcium antagonist nimodipine has been shown to reduce the incidence of
ischemic complications following aneurysmal subarachnoid hemorrhage (SAH). Although …

Nimodipine has been shown to improve outcomes following aneurysmal subarachnoid
hemorrhage. Guidelines recommend that all patients receive a fixed dose of oral nimodipine …

Background Nimodipine is the only medication shown to improve outcomes after
aneurysmal subarachnoid hemorrhage (SAH). Preliminary theories regarding the …

OBJECTIVE The objective of this study was to measure the concentration of nimodipine in
CSF and plasma after intraventricular injection of a sustained-release formulation of …

Background Nimodipine improves outcomes following aneurysmal subarachnoid
hemorrhage (aSAH). Guidelines recommend that all patients should receive a fixed-dose …

Background Oral nimodipine is used for prophylaxis and treatment of delayed cerebral
ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage …